Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
berberine + ProMetS
- Development stage
- Unknown
- Lead developer
- Shanghai Jiao Tong University School of Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Berberine + ProMetS is an investigational combination therapy consisting of berberine hydrochloride and a proprietary probiotic formulation (ProMetS) containing nine strains of Bifidobacterium, Lactobacillus, and Lactococcus. Developed by the Shanghai Jiao Tong University School of Medicine, the combination was evaluated in the PREMOTE study (NCT02332759) for the treatment of newly diagnosed type 2 diabetes mellitus. Berberine, a small molecule alkaloid extracted from Coptis chinensis, acts as an AMPK activator to improve glucose metabolism and insulin sensitivity. The ProMetS probiotic component modulates the gut microbiota, which contributes to improved postprandial lipidemia and glycemic control. The treatment is administered orally, with berberine provided as tablets and ProMetS as a powder.
- Brand names
- ProMetS
- Other names
- berberine + probioticsberberine + ProMetS probiotics
02
Targets
FtsZ (Filamentous temperature-sensitive protein Z)AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on berberine + ProMetS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on berberine + ProMetS.